Arcus Biosciences Reports First Quarter 2021 Financial Results and Provides Operational Highlights

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today reported financial results for the first quarter ended March 31, 2021 and provided operational highlights. “Our ongoing clinical trials include six randomized studies with several that are expected to provide meaningful readouts over...

Click to view original post